Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Roivant Sciences ( (ROIV) ) has issued an announcement.
Roivant Sciences Ltd. announced that its Phase 2 RESOLVE-Lung study of namilumab in treating chronic active pulmonary sarcoidosis failed to show any treatment benefit, leading to the discontinuation of further development. Despite the setback, the study’s data will contribute significantly to future research in sarcoidosis, highlighting the inherent risks in clinical development while underscoring Roivant’s commitment to innovation in medicine.
For a thorough assessment of ROIV stock, go to TipRanks’ Stock Analysis page.